Sign in

You're signed outSign in or to get full access.

General John M. “Jack” Keane (Ret.)

Director at SIGA TECHNOLOGIES
Board

About General John M. “Jack” Keane (Ret.)

General Jack Keane, age 82, joined SIGA’s Board on March 17, 2025 as an independent director. He is a retired U.S. Army General with a 37-year military career, serving as Vice Chief of Staff of the Army from 1999 to 2003. He holds a B.S. in Accounting from Fordham University and a master’s degree in Philosophy from Western Kentucky University, and brings deep national security and biodefense expertise with extensive public company board experience. The Board classified him as independent under Nasdaq rules.

Past Roles

OrganizationRoleTenureCommittees/Impact
U.S. ArmyVice Chief of Staff1999–2003Senior leadership/operations oversight
SCP Partners (VC firm)Venture Partner2009–2012Investment/strategy exposure

External Roles

OrganizationRoleTenureCommittees/Impact
Institute for the Study of WarChairmanSince 2007Strategic leadership in national security research
GSI, LLC (consulting)PresidentSince 2004Defense/national security consulting leadership
IronNet, Inc.Director2015–2023Public board governance (cybersecurity)
General Dynamics Corp.Director2004–2018Public board governance (defense prime)
MetLife, Inc.Director2003–2015Public board governance (financial services)

Board Governance

  • Committee assignments: Not disclosed for Gen. Keane; he joined in March 2025 and 2024 committee rosters list Audit (Marshall – Chair; Nemirovsky; Ford), Compensation (Nemirovsky – Chair; Nabel; Phillips), and Nominating (Durnan – Chair; Marshall; Phillips).
  • Independence: Board determined all nominees other than the CEO are independent under Nasdaq Rule 5605 (Keane included).
  • Attendance: In 2024 the Board held 13 meetings; each incumbent director attended ≥75% of Board/committee meetings and all then-serving directors attended the 2024 annual meeting. (Keane was not on the Board in 2024.)
  • Board leadership: No Chair or Lead Independent Director; committee chairs act as Lead Director as needed; independent directors meet in executive session.
  • Nomination note: Keane was initially recommended to the Nominating Committee by a security holder.

Fixed Compensation

ComponentAmountTiming/Notes
Annual Board retainer (member)$45,000Paid quarterly, in arrears
Audit Committee chair$20,000Paid quarterly, in arrears
Audit Committee member$10,000Paid quarterly, in arrears
Compensation Committee chair$15,000Paid quarterly, in arrears
Compensation Committee member$7,500Paid quarterly, in arrears
Nominating Committee chair$10,000Paid quarterly, in arrears
Nominating Committee member$5,000Paid quarterly, in arrears

Performance Compensation

Equity ElementGrant Value/UnitsVesting/SettlementGrant Timing
Annual RSUs$150,000Vest upon next Annual Meeting; at least 70% settled in stock; up to 30% cash Granted on Annual Meeting date (June 10, 2025 for 2025)
Initial stock options (new director)25,000 optionsVest upon grant (director appointment) Upon initial appointment (Keane’s 25,000 options are vested)
Performance Metrics Tied to Director CompensationStatus
Financial/ESG/TSR metrics for director equityNone disclosed; director RSUs are time-based and initial options vest at grant

Other Directorships & Interlocks

CompanyRoleYearsNotes
IronNet, Inc.Director2015–2023Cybersecurity; no SIGA-related transactions disclosed
General Dynamics Corp.Director2004–2018Defense prime; no SIGA-related transactions disclosed
MetLife, Inc.Director2003–2015Insurance/financial services; no SIGA-related transactions disclosed

Expertise & Qualifications

  • National security and biodefense expertise; senior military leadership and strategic skills; public company governance experience across multiple sectors.
  • Education: B.S. Accounting (Fordham); M.A. Philosophy (Western Kentucky).

Equity Ownership

HolderBeneficial Ownership (shares)% of OutstandingOwnership Details
Gen. John M. “Jack” Keane (Ret.)25,000<1%Consists of vested options exercisable within 60 days
  • Hedging/short sales: Company policy prohibits short selling and restricts hedging without preclearance.
  • Director RSUs settle primarily in stock (≥70%), supporting alignment.
  • No pledging of SIGA stock disclosed for directors.

Governance Assessment

  • Positives: Independent director with deep national security/biodefense domain knowledge and multi-company public board experience, aligning with SIGA’s government contracting and biodefense profile. Initial option grant (25,000, vested) and annual RSU program (primarily stock settlement) support ownership alignment. Independent director executive sessions are regularly held.

  • Watch items: Keane’s committee roles are not yet disclosed and the Board currently has no Lead Independent Director—committee chairs rotate in that capacity. He was recommended by a security holder, which is disclosed and evaluated within independence review. SIGA maintains a related-party HQ lease with a principal stockholder (MacAndrews & Forbes), though no Keane-specific related-party transactions are disclosed.

  • Attendance data: Strong overall Board attendance in 2024 (≥75% for incumbents), but no attendance data yet for Keane given his 2025 appointment.

  • Independence confirmed and committee membership standards meet heightened Nasdaq requirements; director compensation uses standard fees and time-based RSUs; no performance metrics or unusual director pay practices disclosed.

  • No red flags disclosed regarding Keane: no related-party transactions, no pledging/hedging exceptions, and no legal or SEC matters involving him noted in the proxy. Broader company-related-party items (HQ lease; advisory firm of former director) are disclosed and overseen by the Audit Committee.